74 results about "Peripheral Arterial Diseases" patented technology

The invention provides a synthetic polypeptide of Formula I′:or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

The invention provides a synthetic polypeptide of Formula I′:or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

The combination of a HMG CoA reductase inhibitor like a statin, such as simvastatin, with a pFox inhibitor such as trimetazidine (“Simetazidine”) is particularly advantageous for treatment of end-stage complications, such as acute coronary syndrome (ACS) and chronic angina, especially in type II diabetics. The combination therapy is also useful in the treatment and / or prevention of chronic heart failure (CHF) and peripheral arterial disease (PAD). The combination of a nitric oxide (NO) mechanism with increased NO production with pFox inhibition simultaneously treats both the effect and the cause of angina. One or more oral hypoglycemic compounds (biguanides, insulin sensitizers, such as thiazolidinediones, α-glucosidase inhibitors, insulin secretagogues, and dipeptidyl peptidase IV inhibitors), protein kinase C (PKC) inhibitors, and acetyl-CoA carboxylase inhibitors can also be used in combination with the HMG CoA reductase inhibitors and / or pFox inhibitors, especially in type II diabetics, to control glucose levels and treat endothelial dysfunction. The drugs can be given in combination (e.g. a single tablet) or in separate dosage forms, administered simultaneously or sequentially. In the preferred form the statin is given in a dose of between 5 and 80 mg / day in two separate doses, and the pFox inhibitor is administered in a sustained or extended dosage formulation at a dose of 20 mg three times a day or 35 mg two times a day. The dose of the oral hypoglycemic, PKC inhibitor, or acetyl-CoA carboxylase inhibitor varies with the type of drug used.

The invention relates to methods of diagnosing susceptibility to cardiovascular disease, including coronary artery disease. MI, abdominal aorta aneurysm, intracranial aneurysm restenosis and peripheral arterial disease, by assessing the presence or absence of alleles of certain polymorphic markers found to be associates with cardiovascular disease. The invention further relates to kits encompassing reagents for assessing such markers, and methods for assessing the probability of response to therapeutic agents and methods using such markers.

The present invention provides a system for assessing the severity and stage of PAD including at least one sensor that measures skin perfusion pressure; a knowledge base that provides data on lower extremity angiosomes; and a processing device in operable communication with the sensor and the knowledge base, the processing device that outputs a visual representation of at least one of the lower extremity angiosomes that guides the sensor in the mapping of a testing site relative to a target vessel where the skin perfusion pressure measurement will be taken.

The invention relates to the technical field of medical instruments, in particular to a stent graft used for treating peripheral arterial diseases and provided with a branch stent. The stent graft comprises a main stent and the branch stent, the main stent and the branch stent are each provided with a near end, a far end and an inner cavity arranged between the near end and the far end, an opening is formed in the main stent, the main stent and the branch stent are connected through a connector, the connector is provided with a bottom connected with the opening, a top capable of movably entering and exiting the opening and a connection inner cavity arranged between the bottom and the top, and the near end of the branch stent is connected with the top of the connector. The stent graft has the advantages that the stent graft is used for treating vascular diseases, is wide in adaptability, does not need to be customized, can be used for recovering multiple branch arteries when the peripheral arterial diseases are treated, prevents vascular stents from being implanted twice or many times and simplifies operation difficulty.

The invention provides a bioconjugates comprising a synthetic polypeptide of Formula I′ (SEQ ID NO: 1):or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein and a half-life extending moiety wherein the peptide and the half-life extending moiety are covalently linked or fuse, optionally via a linker. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the bioconjugates of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Immunization of a mammal with IL-1α, which causes the mammal to generate IL-1α autoantibodies, can be used to reduce the risk and severity of, or to reduce progression of, an atherosclerosis-related disease in the mammal. Progression of atherosclerosis-related diseases such as peripheral ischemic heart disease, coronary artery disease, cerebrovascular disease, and peripheral arterial disease can be reduced using this treatment.

The invention provides a synthetic polypeptide of Formula I′:or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Compounds represented by formula (I), prodrugs thereof and salts thereof, and pharmaceutical compositions comprising the same as an active ingredient (wherein each symbol has the meaning as defined in the specification.).Because of having an EDG-1 agonism, the compounds represented by formula (I) are useful in preventing and / or treating peripheral arterial disease such as arteriosclerosis obliterans, thromboangiitis obliterans, Buerger's disease or diabetic neuropathy, sepsis, angiitis, nephritis, pneumonia, stroke, myocardial infarction, edematous state, atherosclerosis, varicosity such as hemorrhoid, anal fissure or fistula ani, dissecting aneurysm of the aorta, angina, DIC, pleuritis, congestive heart failure, multiple organ failure, bedsore, burn, chronic ulcerative colitis, Crohn's disease, heart transplantation, renal transplantation, dermal graft, liver transplantation, osteoporosis, pulmonary fibrosis, interstitial pneumonia, chronic hepatitis, liver cirrhosis, chronic renal failure, or glomerular sclerosis.

Hemodynamic data and imaging data are obtained about a patient, and the data is combined to generate a single report integrating same. While a hemodynamic system obtains the hemodynamic data, an imaging system obtains the imaging data. Preferably, the report confirms the absence or presence (and / or severity) of peripheral arterial disease, including quantitative data. The hemodynamic system and the imaging system can communicate directly, indirectly, and / or wirelessly. They may be contained within a common enclosure and / or integrated into a single apparatus. Either or both of the hemodynamic system and / or the imaging system can also be configured to measure the blood pressure of the patient. Preferably, the imaging system is an ultrasound imaging system, and improved workflows for diagnosing peripheral arterial disease result.

The invention provides a cyclic polypeptide of Formula I (SEQ ID NO: 1):X1-R-X3-X4-L-S-X7-X8-X9-X10-X11-X12-X13  Ior an amide, an ester or a salt thereof, or a bioconjugate thereof, wherein X1, X3, X4, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention or bioconjugates thereof, and their therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Compounds represented by formula (I), prodrugs thereof and salts thereof, and pharmaceutical compositions comprising the same as an active ingredient (wherein each symbol has the meaning as defined in the specification.). Because of having an EDG-1 agonism, the compounds represented by formula (I) are useful in preventing and / or treating peripheral arterial disease such as arteriosclerosis obliterans, thromboangiitis obliterans, Buerger's disease or diabetic neuropathy, sepsis, angiitis, nephritis, pneumonia, stroke, myocardial infarction, edematous state, atherosclerosis, varicosity such as hemorrhoid, anal fissure or fistula ani, dissecting aneurysm of the aorta, angina, DIC, pleuritis, congestive heart failure, multiple organ failure, bedsore, burn, chronic ulcerative colitis, Crohn's disease, heart transplantation, renal transplantation, dermal graft, liver transplantation, osteoporosis, pulmonary fibrosis, interstitial pneumonia, chronic hepatitis, liver cirrhosis, chronic renal failure, or glomerular sclerosis.

In accordance with the present invention there is provided a method for the treatment of peripheral arterial diseases in a host comprising administering a therapeutically effective amount of compounds having the formulas (I) through (III) or analogues thereof.

Embodiments described herein are directed to non-invasive detection of peripheral arterial disease. For example, a measuring apparatus is used to measure a patient's calf circumference. The measuring apparatus has text feature(s) or indicator(s) printed thereupon that indicate the likelihood that the patient has peripheral arterial disease based on the measured calf circumference. The assessment may be further refined by using a software application that assesses the likelihood of the patient having peripheral arterial disease using at least the calf circumference measurement, along with other information / data. Based on the assessment, a healthcare practitioner may prescribe a walking program for the patient to follow. A software application may track compliance of the walking program and provide escalating reminders to the patient if the patient continues to fail to comply with the prescribed walking program.

Method for administering streptolysin O to treat various connective tissue disorders in humans and animals such as Dupuytren's contracture, scleroderma, Peyronie's disease, mastistis in animals, and claudication due to peripheral arterial disease.

The invention provides a conjugate, or a pharmaceutically acceptable salt thereof, comprising a synthetic polypeptide of Formula I:Q-R-P-R-L-C*-H-K-G-P-(Nle)-C*-F  (I)or a amide or ester thereof; and a fatty acid selected from:wherein said fatty acid is covalently linked to the N-terminus of the peptide via one of its carboxylic acid functionality, optionally via a polyethylene glycol linker; and wherein the two cysteine amino acids labeled with “*” form a disulfide bond between the thiol functionalities of their side chain. The conjugates are agonist of the APJ receptor. The invention also relates to a method for manufacturing the conjugates of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

The present invention uses neural stem cells in the manufacture of a medicament for the treatment of a patient suffering peripheral arterial disease. The invention is particularly suited for treating limb ischemia or Buerger's disease.

The invention relates to a method for preparing propionyl levocarnitine hydrochloride and application of medicaments thereof. The method comprises the following steps of: (1) mixing and stirring propionic acid and levocarnitine inner salt to prepare propionic acid solution of the levocarnitine inner salt, wherein a mass ratio of the propionic acid to the levocarnitine inner salt is 1:(0.5-1.5); (2) mixing and stirring the propionic acid and propionyl chloride to prepare an acylated reagent, wherein a mass ratio of the propionic acid to the propionyl chloride is 1:(1.5-10); and (3) mixing the propionic acid solution of the levocarnitine inner salt and the acylated reagent, and performing acidylation reaction to obtain the propionyl levocarnitine hydrochloride. The method is mild in condition, safe in reaction, easy to operate and low in cost, and waste gas is not generated. The medicaments which take the propionyl levocarnitine hydrochloride as active ingredients are used for treating peripheral arterial diseases and chronic congestive heart failure to enhance athletic ability, and have a good effect.

The present invention provides a system for assessing the severity and stage of PAD including at least one sensor that measures skin perfusion pressure; a knowledge base that provides data on lower extremity angiosomes; and a processing device in operable communication with the sensor and the knowledge base, the processing device that outputs a visual representation of at least one of the lower extremity angiosomes that guides the sensor in the mapping of a testing site relative to a target vessel where the skin perfusion pressure measurement will be taken.

The invention relates to an indobufen pharmaceutical composition and a quality control method thereof. Particularly, the indobufen pharmaceutical composition contains the following components in parts by weight: 200 parts of indobufen, 30-50 parts of saccharide diluents, 15-40 parts of a fiber diluents, 5-15 parts of a disintegrating agent, 3-8 parts of an adhesive, 1-5 parts of a flow aid and 1-5 parts of a lubricant, wherein the saccharide diluents are selected from mannitol, saccharose, lactose, fructose, glucose, sorbitol, hydrates of the saccharides, and a combination of the saccharides and hydrates. The invention further relates to a preparation method, quality control method and pharmaceutical use of the composition. The indobufen pharmaceutical composition can be used for treating arteriosclerotic ischemic cardiovascular diseases, ischemic cerebrovascular disease and peripheral arterial disease, blood lipid dysbolism, venous thrombosis and diabetes mellitus and preventing thrombosis during extracorporeal circulation operation and presents excellent effects as described in description.

The invention relates to medical application of CREG protein, and in particular relates to application of the CREG protein in preparing a medicine or a medical instrument for preventing and / or treating atherosclerosis or atherosclerosis related diseases (such as coronary heart disease, cerebral apoplexy, abdominal aortic aneurysm and peripheral arterial disease). The invention also relates to application of a recombinant vector for expressing the CREG protein, a recombinant cell containing the recombinant vector, and a preparation capable of inhibiting down-regulation of the expression of the CREG protein inside blood vessel and capable of up-regulating the expression level of the CREG protein side the blood vessel in preparing a medicine or a medical instrument for preventing and / or treating atherosclerosis or atherosclerosis related diseases (such as coronary heart disease, cerebral apoplexy, abdominal aortic aneurysm and peripheral arterial disease).

The invention provides a synthetic polypeptide of Formula I′: X1-R-X3-R-L-X6-X7-K-X9-P-X11-X12-X13 or an amide, an ester, a salt thereof, or a bioconjugate thereof, wherein X1, X3, X6, X7, X9, X11, X12 and X13 are defined herein. The polypeptides and bioconjugates are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides and bioconjugates of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

The present application discloses roles for miR-93 in treating hypoxia and ischemia. Endothelial cells (HUVEC) and myocytes (C2C12) expressed miR-93 and up-regulated miR-93 in response to hypoxia and serum starvation. Over-expression of miR-93 in HUVECs promoted cell proliferation, prevented hypoxia-induced apoptosis, and enhanced endothelial cell tube formation. miR-93 knockdown in HUVECs resulted in increased hypoxia-induced apoptosis and decreased tube formation. Over-expression or knockdown of miR-93 in myocytes resulted in reduced or increased hypoxia-induced apoptosis, respectively. Down-regulation of miR-93 in C57BL / 6 mice with antagomiR resulted in attenuated perfusion recovery (% non-ischemic leg at day-21: Scramble 85.22.9 vs. AntagomiR-93 67.96). Over-expression of miR-93 in BALB / C mice improved perfusion recovery (% non-ischemic leg at day 21: PremiR-93 757.5 vs. Scramble 59.62.5). The present invention encompasses the use of miR-93 and regulation of miR-93 to treat and prevent hypoxia, ischemia, and other injuries, diseases, disorders, and conditions associated with ischemia.

This document provides methods and materials for modulating afferent nerve signals to treat medical conditions such as CHF, CHF respiration, dyspnea, peripheral vascular disease (e.g., peripheral arterial disease or venous insufficiency), hypertension (e.g., age-associated hypertension, resistant hypertension, or chronic refractory hypertension), COPD, sleep apnea, and chronic forms of lung disease where muscle dysfunction is a part of the disease pathophysiology. For example, methods and materials involved in using electrical and / or chemical techniques to block or reduce afferent nerve signals (e.g., nerve signals of group III and / or IV afferents coming from skeletal muscle and / or the kidneys) are provided.

The invention discloses a kit based on 14 SNP loci for evaluating the peripheral arterial disease prevalence risk and further discloses an application for detecting a following 14 SNP locus material in preparing a product for evaluating or auxiliary evaluating of the peripheral arterial disease prevalence risk of a to-be-tested person: rs17817449 locus, rs6567160 locus, rs10938397 locus, rs6265 locus, rs574367 locus, rs4715210 locus, rs4776970 locus, rs11671664 locus, rs6545814 locus, rs9356744 locus, rs261967 locus, rs12597579 locus, rs652722 locus and rs11142387 locus. According to the kit based on 14 SNP loci for evaluating the peripheral arterial disease prevalence risk, 14 BM1 genetic loci and BMI-GRS are integrated, and the PAD prevalence risk is comprehensively evaluated; the genetic loci are tested in a large scale, and the kit is suitable for Chinese people; the test kit is economical, convenient and suitable for large-scale promotion.

The invention provides biomarkers including β-2-microglobulin, Cystatin C, hsCRP and glucose as well as methods for using the biomarkers for diagnosing and / or assessing the risk of peripheral artery disease in a subject. In some embodiments, the subject being tested may be suffering from or at risk of other circulatory diseases, including coronary artery disease. Hemoglobin A1c or other proxies for measuring glucose levels may be substituted for or measured in addition to glucose in the context of the present invention.